Objective To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of patients with active psoriatic arthritis (PsA). Methods This was a phase II, randomised, placebo-controlled, double-blind trial of adults with active PsA (≥3 swollen and ≥3 tender joints and C reactive protein ≥0.3 mg/dL) despite conventional synthetic disease-modifying anti-rheumatic drug, non-steroidal anti-inflammatory drug, and/or oral corticosteroid therapy. Patients were randomised to subcutaneous injections of guselkumab 100 mg or placebo at weeks 0, 4 and every 8 weeks, with placebo crossover to guselkumab at week 24. Dactylitis was scored on a scale of 0–3 on each digit; enthesitis was assessed using the Leeds Enthesitis Index (0–6...
BACKGROUND: The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic arthritis...
Objective: The IL-23 p19-subunit inhibitor guselkumab has been previously compared with other targ...
BACKGROUND: The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic arthritis...
Objective To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of p...
OBJECTIVE: To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of ...
OBJECTIVE: To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of ...
To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of patients wi...
Objective: To further characterize the effect of guselkumab, a selective IL-23p19-subunit inhibito...
OBJECTIVE: To further characterize the effect of guselkumab, a selective interleukin-23p19-subunit i...
BACKGROUND: Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23,...
BACKGROUND: Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23,...
OBJECTIVE: Previous analyses of pooled DISCOVER-1 and DISCOVER-2 data through Week 24 showed signifi...
Objective Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody targeting...
Objective: Assess long-term efficacy and safety of guselkumab, an IL-23p19-subunit inhibitor, in p...
Objective: To investigate serum protein expression in participants with psoriatic arthritis (PsA) an...
BACKGROUND: The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic arthritis...
Objective: The IL-23 p19-subunit inhibitor guselkumab has been previously compared with other targ...
BACKGROUND: The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic arthritis...
Objective To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of p...
OBJECTIVE: To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of ...
OBJECTIVE: To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of ...
To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of patients wi...
Objective: To further characterize the effect of guselkumab, a selective IL-23p19-subunit inhibito...
OBJECTIVE: To further characterize the effect of guselkumab, a selective interleukin-23p19-subunit i...
BACKGROUND: Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23,...
BACKGROUND: Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23,...
OBJECTIVE: Previous analyses of pooled DISCOVER-1 and DISCOVER-2 data through Week 24 showed signifi...
Objective Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody targeting...
Objective: Assess long-term efficacy and safety of guselkumab, an IL-23p19-subunit inhibitor, in p...
Objective: To investigate serum protein expression in participants with psoriatic arthritis (PsA) an...
BACKGROUND: The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic arthritis...
Objective: The IL-23 p19-subunit inhibitor guselkumab has been previously compared with other targ...
BACKGROUND: The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic arthritis...